Source: Eur Respir J 2013; 41: 824-831
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Myles Puja, Nguyen-Van-Tam Jonathan S., Semple Malcolm G., Brett Stephen J., Bannister Barbara, Read Robert C., Taylor Bruce L., McMenamin Jim, Enstone Joanne E., Nicholson Karl G., Openshaw Peter J., Lim Wei Shen. Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. Eur Respir J 2013; 41: 824-831

Member's Comments

No comment yet.

Related content which might interest you: Predictors of adherence to inhaled corticosteroids in children with asthma and their parents in a multi-ethnic population Source: Annual Congress 2007 - Education, communication and quality of life in childhood asthma Year: 2007 Estimate of asthma control and adherence to inhaled corticosteroids in children with asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Meta-analysis of inhaled corticosteroids response in children with asthma. Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics Year: 2019 Children with mild asthma: do they benefit from inhaled corticosteroids? Source: Eur Respir J 2002; 20: 1470-1475 Year: 2002 Inhaled corticosteroid related pneumonia in real world among the patients with asthma and COPD Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 Suboptimal persistence with inhaled corticosteroid (ICS) mono-therapy among children with persistent asthma in the UK Source: Eur Respir J 2006; 28: Suppl. 50, 709s Year: 2006 Mechanisms of exacerbation of respiratory symptoms in patients with COPD Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases Year: 2006 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Differences between asthmatics and nonasthmatics hospitalised with influenza A infection Source: Eur Respir J 2013; 41: 772-774 Year: 2013 Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics Source: Eur Respir J 2001; 17: 380-385 Year: 2001 Risks of pneumonia in asthmatic patients taking inhaled corticosteroids Source: Annual Congress 2010 - Management of airway disease Year: 2010 Treatment of acute asthma Source: Eur Respir Mon 2012; 56: 172-187 Year: 2012 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Effect of different asthma treatments on risk of cold-related exacerbations Source: Eur Respir J 2011; 38: 584-593 Year: 2011 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019 Year: 2019 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019 Year: 2019